“…Moreover, the preliminary results of many other related studies, such as the engineering improvement strategies to existing CAR-T-cell products or the effects induced by multiple factors inside and outside the body, were reported in this meeting. The relevant data about the safety and efficacy of those products, including ciltacabtagene autoleucel (cilta-cel) ( 46 – 48 ), CT053 ( 49 , 50 ), CT103A ( 51 ), C-CAR088 ( 52 ), PHE885 ( 53 ), CART-ddBCMA ( 54 ), and bb21217 ( 55 ), are presented in Table 2 , and the relevant supplementary explanations will be carried out later in this paper.…”